Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

Other

Kumiai Chemical Industry Co., Ltd.

Toyo Jozo Company, Ltd.

Teijin Limited

Mitsui Toatsu Chemicals, Incorporated

Senju Pharmaceutical Co., Ltd.

Yamasu Shoyu Kabushiki Kaisha

Itaru Yamamoto

Toshio Miyake

Norio Muto

Kensuke Shibata

Noriyasu Takayanagi

Kenji Matsunari

Koyata Nitta

Kenji Sasaki

Kazumi Ogata

Kanji Tomiya

Akira Matsubara

Hideki Tsuruta

Mikio Kumakura

Toru Takeshita

Kenji Ishimaru

Osamu Nishikawa

Jun-ichi Oshida

Yoshihito Fujinami

Mitsuhiro Sakaguchi

Osamu Mizuno

Akihiro Tai

Shino Okazaki

Acyl derivatives of glycosyl-L-ascorbic acids which have a higher oil-solubility than L-ascorbic acid, glycosyl-L-ascorbic acids, and inorganic esters of L-ascorbic acid such as phosphates and sulfates of L-ascorbic acid. When administered to living bodies, the acyl derivatives easily permeate into living tissues to release L-ascorbic acid, resulting in an exertion of the physiological action inherent to L-ascorbic acid. Thus, the derivatives can be arbitrarily used in food products, cosmetics, and pharmaceuticals.

Acyl derivatives of glycosyl-L-ascorbic acid

.alpha.-Glycosyl-L-ascorbic acid exhibiting no direct reducing activity is formed in a solution containing L-ascorbic acid and an .alpha.-glucosyl saccharide when subjected to the action of a saccharide-transferring enzyme. .alpha.-Glycosyl-L-ascorbic acid is superiorly stable, and readily hydrolyzable in vivo to exhibit the activities inherent to L-ascorbic acid. Thus, .alpha.-glycosyl-L-ascorbic acid is favorably useful as a stabilizer, quality-improving agent, antioxidant, physiologically active agent and uv-absorbent in food pharmaceutical and cosmetic industries.

.alpha.-glycosyl-L-ascorbic acid, and it's preparation and uses

.alpha.-glycosyl-L-ascorbic acid, and its preparation and uses

.alpha.-Glycosyl-L-ascorbic acid, and its preparation and uses

Novel phosphoric diesters of general formula: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and each means a methyl group or a hydrogen atom, provided that at least one of R.sub.1 and R.sub.2 is a hydrogen atom, or a salt thereof which can be produced by reacting .beta., .gamma. or .delta.-tocopherol with a halophosphorylating agent such as phosphorus oxychloride, reacting the resultant product with ascorbic acid whereof hydroxyl groups at 5- and 6-positions are protected, and then removing protected groups from the hydroxyl groups. The phosphoric diester has antiinflammatory activity.

Novel phosphoric diesters

5,6-dihydroimidazo[2,1-b]thiazole-2-carboxamide derivatives represented by the following general formula [I] ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are either the same or different and mean individually a hydrogen atom or lower alkyl group, Y denotes a specific phenyl-containing substituted amino group, and their salts. These compounds have excellent immuno-modulating activities.

5,6-dihydroimidazo[2,1-b]thiazole-2-carboxamide derivatives of salts

A novel 1,2-dithiol-3-thione derivative which has an immunomodulating property, which is expressed by the formula (I): ##STR1## wherein R denotes hydrogen, halogen, lower alkoxy group, lower alkyl group, amino group, lower alkyl-substituted amino group or lower alkoxycarbonyl group.

Immunomodulator 1,2-dithiol-3-thione derivative composition, use method

5,6-dihydroimidazo(2,1-b)thiazole-2-carboxamide derivatives or salts

A pharmaceutical composition useful as immunomodulator comprising an effective amount of a trithiazole pentamethine cyanine derivative having the following general formula (I): ##STR1## wherein R is an alkyl group having 1 to 15 carbon atoms, and X is a halogen atom, or a residual group of perchloric acid, nitric acid or an organic acid. The composition is useful for the prevention and treatment of various types of immune diseases, particularly rheumatoid arthritis.

Immunomodulator containing trithiazole pentamethine cyanine derivative

The present invention relates to novel vitamin D.sub.3 derivatives which have a carboxyl group or its ester group at the 22-position, processes for the preparation thereof, and antigens, which comprise said vitamin D.sub.3 derivative and an immunogenic carrier material, to be used for the preparation of antibodies for enzymeimmunoassay or radioimmunoassay and antibodies obtained therefrom. The determination of such activated vitamin D.sub.3 compounds as 25-hydroxy vitamin D.sub.3, 24, 25-dihydroxy vitamin D.sub.3, etc. can be made satisfactorily according to the present invention.

Vitamin D.sub.3 derivatives, process for preparation thereof, and

A method of quantitative analysis of cyclic nucleotides which comprises: acylating a cyclic nucleotide in an assay sample by using an acylating agent; causing said acyl-cyclic nucleotide and a specific quantity of an enzyme-labeled cyclic nucleotide formed by bonding a cyclic nucleotide corresponding to the acyl-cyclic nucleotide and an enzyme through a dicarboxylic acid to undergo competitive reaction with a specific quantity of an antibody with respect to a corresponding cyclic nucleotide; separating the enzyme-labeled cyclic nucleotide which has become bonded to said antibody and the enzyme-labeled cyclic nucleotide which has not become bonded thereto; and determining the quantity of the cyclic nucleotide by measuring the enzyme activity of either of the enzyme-labeled cyclic nucleotides. For this analysis, a reagent comprising an enzyme-labeled cyclic nucleotide is used.

Method of and reagents for quantitative analysis of cyclic nucleotides

Growing community of inventors

Okayama, Japan

Itaru Yamamoto